2026 VB100: China's Top 50 Ecological Innovation & Empowerment Platforms in Healthcare Unveil IPO Prospectus

The healthcare industry is entering a critical phase of ecosystem-driven collaborative innovation. Platform-based entities such as industrial parks, incubators, and innovation centers have become core nodes in the ecological infrastructure, linking upstream and downstream segments of the industry chain, aggregating global innovation resources, and nurturing high-potential, high-quality enterprises.

From the layout of national-level biopharmaceutical industrial parks, to the intensive rollout of local innovation incubation policies, and further to the explicit support for key sectors such as the bioeconomy and the silver economy in the 15th Five-Year Plan, the construction of the industrial ecosystem has been elevated to the level of national strategy.

In this context, the 2026 Future Healthcare Top 100 has launched the “Top 50 Ecosystem Innovation and Empowerment Platforms in China’s Healthcare Industry,” aligning with the new development paradigm characterized by the symbiotic and mutually reinforcing growth of diverse entities within the industrial ecosystem. The selection focuses on various platform types, including industrial parks, incubators, and innovation centers. It evaluates not only their value and effectiveness in areas such as spatial infrastructure, resource coordination, project incubation, and technological empowerment, as well as their regional industrial influence, but also delves into the differentiated core values of each platform.

For a long time, the industry’s evaluation of industrial platforms has focused more on metrics such as land area, the number of tenant enterprises, and park output value. However, as industries enter a phase of deep collaboration, these indicators are no longer sufficient to reflect the true value of a platform. After all, the core competitiveness of a platform lies in its ability to facilitate enterprise growth.

Based on this assessment, the evaluation framework has been restructured for this selection.

Industrial parks are primarily evaluated on their policy support and resource assurance capabilities, enterprise cultivation and industrial agglomeration capabilities, as well as regional driving force and sustainable development capabilities. Key focus areas include specialized policy frameworks for healthcare companies, the depth of industry-academia-research-medical collaboration, allocation of industrial funds, the scale and quality of tenant enterprises, supply chain synergies, and the role in stimulating regional industrial growth.

Incubators are evaluated primarily on their incubation resources and collaborative support capabilities, project cultivation and incubation effectiveness, and innovative incubation and sustainable development capabilities. Key focus areas include industry-academia-research-medical collaboration resources, alignment with industrial funds, configuration of professional mentor teams, as well as core incubation outcomes such as the number of incubated projects, graduation rates, and output of technological achievements.

The Innovation Center focuses on evaluating capabilities in scientific research collaboration and technical support, technology transfer and industry empowerment, as well as innovation leadership and sustainable development. It places particular emphasis on deep industry-academia-research-medical collaboration, the configuration of high-end scientific research equipment, the strength of core R&D teams, the volume of technological achievement transfers, cooperation with industrial funds, case studies of enterprise technology empowerment, and participation in the formulation of industry standards.

Competition in the healthcare industry platform is shifting from "scale competition" to "enablement competition."

This selection process reveals three distinct trends emerging in China’s healthcare industry platforms.

I. From Geographical Clustering to Deep Multi-Party Collaboration

In the past, the value of industry platforms was primarily reflected in shared office spaces, communal use of instruments and equipment, and collective access to policy incentives. Today, however, truly valuable platforms are beginning to foster sustained interaction among technology, capital, clinical practice, and industrial resources. Companies are no longer merely co-located within the same industrial park; they are starting to form genuine industrial synergies.

II. From Standardized Services to More Precise Empowerment

The diverging needs of companies at different stages and in different sectors are becoming increasingly pronounced. Early-stage projects focus on proof of concept and financing support; growth-stage enterprises require greater assistance with market access, channel expansion, and scaled-up production to accelerate commercialization; while mature companies are beginning to prioritize internationalization and supply chain integration.

Leading platforms are building more refined service systems around these differentiated needs.

III. From Local Services to Global Connectivity

As Chinese innovative drugs and medical devices continue to expand into global markets, an increasing number of platforms are proactively engaging with international resources, including overseas capital, multinational pharmaceutical companies, international clinical trial networks, and global regulatory systems. For Chinese innovative enterprises, the internationalization capabilities of these platforms are becoming a new and critical variable.

The formation of these trends is both a result of the platforms’ own evolution and an inevitable outcome driven by industrial demands. Currently, competition in the healthcare industry has become a contest of platform capabilities, resource systems, and industrial synergy efficiency.

This selection process broadens perspectives and delves deep into value to identify benchmark enabling platforms, establishing ecological infrastructure benchmarks that are comparable and replicable for the high-quality, ecosystem-driven development of the healthcare industry. Meanwhile, it also provides entrepreneurs, local governments and park managers, and investment institutions with references for capability assessment, benchmarking samples, and insights into emerging trends.

For the platforms on the list, this ranking signifies new responsibilities. How they continuously enhance their platform capabilities, help enterprises navigate the R&D and commercialization cycles, and truly become a long-term supporting force for industrial innovation will determine their future position in the industry.

“Top 50 Ecological Innovation and Empowerment Platforms in China’s Healthcare Industry 2026” has been2026 Future Healthcare Top 100 Awards CeremonyAnnounced on-site, the strategic partner for this awards ceremony isHSBC Sci-Tech Innovation Finance。The following are the selected posters: